文献速递传染病防控与疫情报告卫生政策与健康促进

爱沙尼亚SARS-CoV-2 IgG抗体流行率及其与COVID-19临床症状的关联(KoroSero-EST-1研究)

Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).
PubMed 文献 · Vaccine · 2021-08-05

该研究在爱沙尼亚塔林和萨雷马岛通过分层随机抽样招募1960人,采用四种方法检测IgG或中和抗体。塔林和萨雷马岛的血清流行率分别为1.5%(95%CI 0.9-2.5)和6.3%(95%CI 5.0-7.9),感染致死率分别为0.1%(95%CI 0.0-0.2)和1.3%(95%CI 0.4-2.1)。仅关注呼吸道症状可能延迟SARS-CoV-2感染的准确诊断。

要点

  • 塔林和萨雷马岛血清流行率分别为1.5%和6.3%,多数人群仍易感。
  • 50岁及以上人群中,发热、腹泻及无咳嗽和流涕与血清阳性相关。
  • 仅关注呼吸道症状可能延迟SARS-CoV-2感染的准确诊断。

核心结论

  • 爱沙尼亚SARS-CoV-2血清流行率低,即使热点地区萨雷马岛也仅6.3%,多数人群易感。
  • 仅关注呼吸道症状可能延迟SARS-CoV-2感染的准确诊断。

研究设计与样本

  • 采用分层(按年龄十年分组)随机抽样,由全科医生招募参与者。
  • 从2020年5月8日至7月31日邀请3608人,招募1960人。
  • 用四种方法从血清中检测IgG或中和抗体。
  • 用多重对应分析分析与血清阳性相关的症状,用多元线性回归分析抗体浓度。

主要发现

  • 塔林和萨雷马岛的血清流行率分别为1.5%(95%CI 0.9-2.5)和6.3%(95%CI 5.0-7.9)。
  • 塔林和萨雷马岛的感染致死率分别为0.1%(95%CI 0.0-0.2)和1.3%(95%CI 0.4-2.1)。
  • 血清阳性者中19.2%(14/73)有急性呼吸道疾病。
  • 50岁及以上人群中,发热、腹泻及无咳嗽和流涕与血清阳性相关。
  • 若有发热、呼吸困难、气短、胸痛或腹泻,或需住院,IgG浓度更高,但中和抗体浓度无此关联。

临床怎么用

  • 在低流行区应结合症状谱(包括发热、腹泻及无咳嗽流涕)识别可疑病例,避免仅凭呼吸道症状漏诊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In Estonia, during the first wave of COVID-19 total number of cases confirmed by PCR was 13.3/10,000, similar in most regions, including capital Tallinn, but in the hotspot of Estonian epidemic, an island Saaremaa, the cumulative incidence was 166.1/10,000. We aimed to determine the prevalence of SARS-CoV-2 IgG antibodies in these two regions, symptoms associated with infection and factors associated with antibody concentrations. METHODS: Participants were selected using stratified (formed by age decades) random sampling and recruited by general practitioners. IgG or neutralizing antibodies were determined from sera by four assays. Symptoms associated with seropositivity were analyzed by multiple correspondence analysis, antibody concentrations by multiple linear regression. RESULTS: Total of 3608 individual were invited and 1960 recruited from May 8 to July 31, 2020. Seroprevalence was 1.5% (95% confidence interval (CI) 0.9-2.5) and 6.3% (95% CI 5.0-7.9), infection fatality rate 0.1% (95% CI 0.0-0.2) and 1.3% (95% CI 0.4-2.1) in Tallinn and Saaremaa, respectively. Of seropositive subjects 19.2% (14/73) had acute respiratory illness. Fever, diarrhea and the absence of cough and runny nose were associated with seropositivity in individuals aged 50 or more years. IgG, but not neutralizing antibodies concentrations were higher if fever, difficulty breathing, shortness of breath, chest pain or diarrhea was present, or hospitalization required. CONCLUSION: Similarly to other European countries the seroprevalence of SARS-CoV-2 in Estonia was low even in the hotspot region Saaremaa suggesting that majority of population is susceptible to SARS-CoV-2. Focusing only on respiratory symptoms may delay accurate diagnosis of SARS-CoV-2 infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Jõgi P, Soeorg H, Ingerainen D, et al. Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study). Vaccine. 2021. PMID: 34393019. doi:10.1016/j.vaccine.2021.07.093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。